Comparative study of commercially available anti-alpha-synuclein antibodies.

Neuropathology and Applied Neurobiology
E CroisierF Roncaroli

Abstract

Immunohistochemistry for alpha-synuclein has become the histological technique of choice for the diagnosis for Parkinson's disease, Dementia with Lewy bodies and Multiple System Atrophy (http://www.ICDNS.org). Nevertheless, no standardised protocol has been proposed. We have reviewed 242 of the 270 studies published until June 2005 that mentioned immunohistochemistry for anti-alpha synuclein on human tissue and we found that only 75 (31%) used commercial antibodies. We also noted that protocols, particularly dilution and antigen unmasking, varied between studies, even when the same antibody was employed. In order to establish a standardised protocol for alpha-synuclein immunohistochemistry, which can be applied in diagnostic neuropathology we tested seven commercial monoclonal antibodies in brains of subjects with Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, multiple sclerosis with incidental Lewy bodies and aged-matched normal brain and determined for each antibody the best suited protocol for antigen unmasking. We evaluated the intensity of immunolabelling in Lewy bodies, neuropil threads, dendrites, pre-synaptic terminals, granular cytoplasmic positivity, peri-axonal positivity, glial inclusions a...Continue Reading

References

May 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·M G SpillantiniM Goedert
Sep 27, 2000·Journal of Neuropathology and Experimental Neurology·J E DudaJ Q Trojanowski
Jul 2, 2003·Journal of Neuropathology and Experimental Neurology·Yuko SaitoShigeo Murayama

❮ Previous
Next ❯

Citations

Jul 16, 2008·Acta Neuropathologica·Thomas G BeachCharles H Adler
Apr 29, 2009·Acta Neuropathologica·Thomas G BeachUNKNOWN Arizona Parkinson's Disease Consortium
Nov 23, 2012·The Journal of Biological Chemistry·Michael HelwigIris Lindberg
Jan 23, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Claudio Ruffmann, Laura Parkkinen
Dec 17, 2009·Journal of Neuropathology and Experimental Neurology·Maria PikkarainenIrina Alafuzoff
Jan 26, 2008·Journal of Neuropathology and Experimental Neurology·Irina AlafuzoffUNKNOWN BrainNet Europe Consortium
Jul 8, 2008·Parkinsonism & Related Disorders·M E KalaitzakisS M Gentleman
Aug 10, 2006·Journal of Neuropathology and Experimental Neurology·Irina AlafuzoffHans Kretzschmar
Jul 15, 2015·Neuroscience Letters·Iban AldecoaEduard Tolosa
Feb 1, 2013·Neuropathology and Applied Neurobiology·M E KalaitzakisR K B Pearce
Aug 13, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Alvaro Sánchez-FerroJosé Antonio Molina-Arjona
Oct 28, 2014·The European Journal of Neuroscience·Alicia Flores-CuadradoAlino Martinez-Marcos
Nov 17, 2009·Lancet Neurology·Dennis W DicksonIrene Litvan
Aug 21, 2007·Experimental Neurology·Glenda M Halliday, Heather McCann
Mar 27, 2016·Annals of Neurology·Morten Gersel StokholmPer Borghammer
Jul 28, 2016·Proceedings of the National Academy of Sciences of the United States of America·Timothy S JarvelaIris Lindberg
Mar 1, 2016·Journal of Neurochemistry·Wouter Peelaerts, Veerle Baekelandt
Feb 6, 2019·Acta Neuropathologica·Lien VeysLies De Groef
May 6, 2019·Journal of Neurochemistry·Nishant N VaikathOmar M A El-Agnaf
Feb 23, 2020·Journal of Parkinson's Disease·Serena SinghMari L DeMarco
Jul 31, 2016·Clinical Chemistry and Laboratory Medicine : CCLM·Marthe Gurine FørlandJohannes Lange
Jan 23, 2021·NPJ Parkinson's Disease·Alicia Flores-CuadradoIsabel Ubeda-Bañon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.